Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yeqing Chen

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Cancer Immunology Research|June 11, 2026
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cellsShujing Liu, Alain H Rook, Alexander C Huang, et al.
Cancers|June 26, 2026
The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal MelanomaMir Mustafa Ali, Md Alauddin, Iqbal Mahmud, et al.
The American Journal of Pathology|October 31, 2024
Programmed Death Ligand-1 in Melanoma and Extracellular Vesicles Promotes Local and Regional Immune Suppression through M2-like Macrophage PolarizationLili Huang, Jingbo Yang, Jinjin Zhu, et al.
Science Advances|January 15, 2025
Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cellsYeye Guo, Huaishan Wang, Shujing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2025
Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal MelanomasYunyan Li, Ziyang Cui, Xiaole Song, et al.
Iscience|February 18, 2026
Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatmentVito W Rebecca, Min Xiao, Andrew Kossenkov, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistanceHaiyin Li, Yeqing Chen, Jessica Kaster, et al.
Nature Communications|January 14, 2021
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapyMatthias Gromeier, Michael C Brown, Gao Zhang, et al.
Nature|July 19, 2023
Diverse clonal fates emerge upon drug treatment of homogeneous cancer cellsYogesh Goyal, Gianna T Busch, Maalavika Pillai, et al.
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Cancer Immunology Research|June 11, 2026
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cellsShujing Liu, Alain H Rook, Alexander C Huang, et al.
Cancers|June 26, 2026
The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal MelanomaMir Mustafa Ali, Md Alauddin, Iqbal Mahmud, et al.
The American Journal of Pathology|October 31, 2024
Programmed Death Ligand-1 in Melanoma and Extracellular Vesicles Promotes Local and Regional Immune Suppression through M2-like Macrophage PolarizationLili Huang, Jingbo Yang, Jinjin Zhu, et al.
Science Advances|January 15, 2025
Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cellsYeye Guo, Huaishan Wang, Shujing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2025
Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal MelanomasYunyan Li, Ziyang Cui, Xiaole Song, et al.
Iscience|February 18, 2026
Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatmentVito W Rebecca, Min Xiao, Andrew Kossenkov, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistanceHaiyin Li, Yeqing Chen, Jessica Kaster, et al.
Nature Communications|January 14, 2021
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapyMatthias Gromeier, Michael C Brown, Gao Zhang, et al.
Nature|July 19, 2023
Diverse clonal fates emerge upon drug treatment of homogeneous cancer cellsYogesh Goyal, Gianna T Busch, Maalavika Pillai, et al.
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Pageof 8